Bank of America says GLP-1 weight-loss drugs are driving 13% of its annual healthcare spending

Bank of America has become one of the latest large employers to quantify the financial impact of GLP-1 drugs, including weight-loss medications that have surged in use in the past few years. CEO Brian Moynihan said the bank is spending about $250 million a year on GLP-1 medications and that the class now accounts for roughly 13% of Bank of America’s total annual healthcare spending.

The figures underscore how GLP-1 treatment has shifted from a niche medical option to a mainstream driver of benefits costs for companies that sponsor health plans, either directly or through employee benefits arrangements. For insurers and large plan sponsors, medication spending can be a large component of overall medical cost trend, and GLP-1s are typically priced and managed differently than many traditional chronic-care therapies.

Moynihan’s comments, reported in a market news report dated August 5, were framed around the bank’s broader view of healthcare cost trends. The company did not provide additional breakdowns in the report about how the $250 million figure was calculated, such as whether it covers only pharmacy benefits or includes other components like administration, rebates, or specialty cost allocations.

The report also did not specify whether the GLP-1 spending measure reflects only weight-loss formulations or a wider set of GLP-1 therapies used for other indications. GLP-1 is a drug class that includes products approved for weight management as well as for certain forms of diabetes and related conditions, which can influence plan utilization and employer cost mix.

For Bank of America, the reported cost share highlights a practical risk for large employers. Even when employers budget for general healthcare inflation, a single drug class that rapidly expands in eligibility and uptake can outpace assumptions used for annual plan design and premium rate setting. Benefits leaders often respond by adjusting pharmacy strategy, prior authorization, step therapy, and plan design features intended to manage utilization and cost.

More broadly, the employer cost picture for GLP-1s has become a focus across the corporate benefits market because usage has increased quickly, and because the drugs can be expensive relative to many other medication categories. As the patient population grows and treatment becomes longer-term for many users, total cost exposure for employers can rise even if any individual patient’s dosing pattern changes over time.

Still, the bank did not disclose details in the report that would be needed to fully interpret the number. It did not describe how many employees or covered dependents are receiving GLP-1 treatments, whether the spending is concentrated in a small portion of high-cost members, or how factors like changes in plan participation, benefit tiering, or preferred pharmacy arrangements may be affecting the $250 million figure.

What to watch next is whether Bank of America and peers provide more granular transparency in upcoming earnings or benefits updates. Specifically, investors and benefits professionals will likely look for guidance on how GLP-1-related spending trends feed into cost projections, whether employers expect pricing or utilization to stabilize, and what plan design measures are being considered to manage the pace of cost growth.